Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma

NCT06904170 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

196

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Durvalumab Plus Tremelimumab
DRUG: HAIC (GEMOX)

Sponsor

UNICANCER

Collaborators

[object Object]